Medical Data Vision Co., Ltd. (Chiyoda-ku, Tokyo; President and CEO: Hiroyuki Iwasaki; hereinafter referred to as “MDV”), which owns one of the largest medical database in Japan, is pleased to announce the launch of a new version of MDV Analyzer©, which includes the new “DEEP DIVE” functionality. This enhanced feature allows for detailed analysis and aggregation of results obtained from analyzing and summarizing data according to specific criteria.
With the “DEEP DIVE” function, users can further explore and analyze data by adding new criteria to previously analyzed and aggregated data. For instance, it enables users to delve deeper into aspects such as prescription quantities for specific medications, incorporating factors like age and gender. It also allows for the examination of concurrent medication usage among patients. This feature is particularly valuable for pharmaceutical companies and other users as it offers several advantages:
In-Depth Clinical Insights: Users can gain a comprehensive understanding of clinical realities related to medications, enabling them to provide physicians with more precise information.
Tailored Marketing Strategies: With a solid foundation of clinical insights, users can create marketing strategy materials and reports that are grounded in real-world data.
Flexibility: Even if new criteria need to be added during the analysis and aggregation process, users can seamlessly continue their work, reducing the time required for analysis and speeding up the process.
This new “Deep Dive” functionality enhances the capabilities of MDV Analyzer, making it a versatile tool for extracting valuable insights from medical data.
What Can Be Achieved with MDV Analyzer+ (Plus)
- High-Precision Information Delivery to Physicians
- Development of Marketing Strategies Based on Prescription Realities
- Reduction in Analysis and Aggregation Time
MDV continues to accumulate anonymized and licensed secondary-use data obtained from medical institutions. As of August 2023, the hospital database includes data from 44.72 million patients. Additionally, data from insurance providers, including health insurance, national health insurance, and late-stage elderly insurance, has expanded to 19.52 million individuals through various collaborations, such as the one with DeNA Co., Ltd., in May of the previous year.
In July of this year, MDV Analyzer introduced an “Extrapolation function” feature, which calculates disease prevalence for each type of insurance data after cross-referencing with ledger information. This functionality enables the calculation of nationwide values using data not only from hospital records but also from the entire population and all subscribers of various insurance providers and municipalities.
